Back to Search Start Over

Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes.

Authors :
Schramm, Catherine
Charbonnier, Camille
Zaréa, Aline
Lacour, Morgane
Wallon, David
CNRMAJ collaborators
Andriuta, Daniela
Anthony, Pierre
Auriacombe, Sophie
Balageas, Anna-Chloé
Ballan, Guillaume
Barbay, Mélanie
Beaufils, Emilie
Béjot, Yannick
Belliard, Serge
Benaiteau, Marie
Bennys, Karim
Blanc, Frédéric
Bombois, Stéphanie
Boutoleau Bretonnière, Claire
Source :
Genome Medicine; 8/4/2022, Vol. 14 Issue 1, p1-15, 15p
Publication Year :
2022

Abstract

Background: Alzheimer disease (AD) is a common complex disorder with a high genetic component. Loss-of-function (LoF) SORL1 variants are one of the strongest AD genetic risk factors. Estimating their age-related penetrance is essential before putative use for genetic counseling or preventive trials. However, relative rarity and co-occurrence with the main AD risk factor, APOE-ε4, make such estimations difficult. Methods: We proposed to estimate the age-related penetrance of SORL1-LoF variants through a survival framework by estimating the conditional instantaneous risk combining (i) a baseline for non-carriers of SORL1-LoF variants, stratified by APOE-ε4, derived from the Rotterdam study (N = 12,255), and (ii) an age-dependent proportional hazard effect for SORL1-LoF variants estimated from 27 extended pedigrees (including 307 relatives ≥ 40 years old, 45 of them having genotyping information) recruited from the French reference center for young Alzheimer patients. We embedded this model into an expectation-maximization algorithm to accommodate for missing genotypes. To correct for ascertainment bias, proband phenotypes were omitted. Then, we assessed if our penetrance curves were concordant with age distributions of APOE-ε4-stratified SORL1-LoF variant carriers detected among sequencing data of 13,007 cases and 10,182 controls from European and American case-control study consortia. Results: SORL1-LoF variants penetrance curves reached 100% (95% confidence interval [99–100%]) by age 70 among APOE-ε4ε4 carriers only, compared with 56% [40–72%] and 37% [26–51%] in ε4 heterozygous carriers and ε4 non-carriers, respectively. These estimates were fully consistent with observed age distributions of SORL1-LoF variant carriers in case-control study data. Conclusions: We conclude that SORL1-LoF variants should be interpreted in light of APOE genotypes for future clinical applications. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1756994X
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
Genome Medicine
Publication Type :
Academic Journal
Accession number :
158365715
Full Text :
https://doi.org/10.1186/s13073-022-01070-6